Drugs / 15-valent HPV Vaccine
15-valent HPV Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06454175 | Aug 2024 → Feb 2025 | anogenital human papillomavirus infection, human papillomavirus-related squamous cell carcinoma, intraepithelial neoplasia | Shanghai Bovax Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 15-valent HPV Vaccine | “A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years” NCT06454175 ↗ |
| Known as | 15-HPV vaccine | “3 doses of the 15-HPV vaccine” NCT06454175 ↗ |
| Known as | 15-valent Human Papillomavirus Recombinant Vaccine | “A Randomised, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of 15-valent Human Papillomavirus Recombinant Vaccine...” NCT06454175 ↗ |
| Modality | Vaccine | “15-valent HPV vaccine” NCT06454175 ↗ |
| Route | Intramuscular | “intramuscular injection of the upper arm deltoid muscle” NCT06454175 ↗ |